Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.